Advent Pharma Ltd. (DSE:ADVENT)
Bangladesh
· Delayed Price · Currency is BDT 13.20
-0.50 (-3.65%)
At close: Mar 5, 2026
Advent Pharma Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2020 - 2016 |
| Revenue | 516.48 | 500.49 | 571.67 | 558.05 | 530.47 | 503.6 | Upgrade
|
| Revenue Growth (YoY) | 2.10% | -12.45% | 2.44% | 5.20% | 5.34% | -5.70% | Upgrade
|
| Cost of Revenue | 355.28 | 324.86 | 343.77 | 335.14 | 310.31 | 288 | Upgrade
|
| Gross Profit | 161.2 | 175.63 | 227.9 | 222.91 | 220.16 | 215.61 | Upgrade
|
| Selling, General & Admin | 78.2 | 80.04 | 86.26 | 87.55 | 86.78 | 79.18 | Upgrade
|
| Operating Expenses | 78.2 | 80.04 | 86.26 | 87.55 | 86.78 | 79.18 | Upgrade
|
| Operating Income | 83 | 95.58 | 141.65 | 135.36 | 133.38 | 136.42 | Upgrade
|
| Interest Expense | -9.01 | -9.16 | -8.09 | -6.63 | -4.11 | -4.9 | Upgrade
|
| Interest & Investment Income | 0.02 | 0.02 | 0.02 | 0.01 | 1.1 | 2.93 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.16 | -0.16 | -0.18 | -0.11 | -0.08 | 0.12 | Upgrade
|
| EBT Excluding Unusual Items | 73.85 | 86.29 | 133.39 | 128.63 | 130.3 | 134.58 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | -29.61 | - | - | -0.39 | Upgrade
|
| Pretax Income | 73.85 | 86.29 | 103.78 | 128.63 | 130.3 | 134.19 | Upgrade
|
| Income Tax Expense | 16.62 | 19.41 | 19.79 | 29.99 | 32.76 | 20.6 | Upgrade
|
| Net Income | 57.23 | 66.87 | 83.99 | 98.64 | 97.53 | 113.59 | Upgrade
|
| Net Income to Common | 57.23 | 66.87 | 83.99 | 98.64 | 97.53 | 113.59 | Upgrade
|
| Net Income Growth | -2.09% | -20.38% | -14.85% | 1.14% | -14.14% | -2.96% | Upgrade
|
| Shares Outstanding (Basic) | 93 | 93 | 93 | 93 | 93 | 93 | Upgrade
|
| Shares Outstanding (Diluted) | 93 | 93 | 93 | 93 | 93 | 93 | Upgrade
|
| Shares Change (YoY) | -0.63% | - | - | - | - | - | Upgrade
|
| EPS (Basic) | 0.62 | 0.72 | 0.90 | 1.06 | 1.05 | 1.22 | Upgrade
|
| EPS (Diluted) | 0.62 | 0.72 | 0.90 | 1.06 | 1.05 | 1.22 | Upgrade
|
| EPS Growth | -1.47% | -20.38% | -14.85% | 1.14% | -14.14% | -2.96% | Upgrade
|
| Free Cash Flow | 8.73 | 20.56 | 13.08 | 2.56 | -11.56 | -3.67 | Upgrade
|
| Free Cash Flow Per Share | 0.09 | 0.22 | 0.14 | 0.03 | -0.12 | -0.04 | Upgrade
|
| Dividend Per Share | - | 0.050 | 0.100 | 0.200 | 0.200 | 0.196 | Upgrade
|
| Dividend Growth | - | -50.00% | -50.00% | - | 1.99% | - | Upgrade
|
| Gross Margin | 31.21% | 35.09% | 39.87% | 39.95% | 41.50% | 42.81% | Upgrade
|
| Operating Margin | 16.07% | 19.10% | 24.78% | 24.26% | 25.14% | 27.09% | Upgrade
|
| Profit Margin | 11.08% | 13.36% | 14.69% | 17.68% | 18.39% | 22.56% | Upgrade
|
| Free Cash Flow Margin | 1.69% | 4.11% | 2.29% | 0.46% | -2.18% | -0.73% | Upgrade
|
| EBITDA | 144.34 | 158.05 | 207.57 | 193.96 | 175.07 | 174.59 | Upgrade
|
| EBITDA Margin | 27.95% | 31.58% | 36.31% | 34.76% | 33.00% | 34.67% | Upgrade
|
| D&A For EBITDA | 61.34 | 62.47 | 65.93 | 58.6 | 41.69 | 38.17 | Upgrade
|
| EBIT | 83 | 95.58 | 141.65 | 135.36 | 133.38 | 136.42 | Upgrade
|
| EBIT Margin | 16.07% | 19.10% | 24.78% | 24.26% | 25.14% | 27.09% | Upgrade
|
| Effective Tax Rate | 22.50% | 22.50% | 19.07% | 23.31% | 25.15% | 15.35% | Upgrade
|
| Advertising Expenses | - | 0.12 | 0.15 | 0.19 | 0.18 | 0.15 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.